KR20230096975A - 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법 - Google Patents

사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법 Download PDF

Info

Publication number
KR20230096975A
KR20230096975A KR1020237010389A KR20237010389A KR20230096975A KR 20230096975 A KR20230096975 A KR 20230096975A KR 1020237010389 A KR1020237010389 A KR 1020237010389A KR 20237010389 A KR20237010389 A KR 20237010389A KR 20230096975 A KR20230096975 A KR 20230096975A
Authority
KR
South Korea
Prior art keywords
subject
cyclodextrin
beta
hydroxypropyl
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237010389A
Other languages
English (en)
Korean (ko)
Inventor
다이애나 커윈
제이슨 캠
Original Assignee
베렌 테라퓨틱스 피.비.씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베렌 테라퓨틱스 피.비.씨. filed Critical 베렌 테라퓨틱스 피.비.씨.
Publication of KR20230096975A publication Critical patent/KR20230096975A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
KR1020237010389A 2020-08-27 2021-08-27 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법 Withdrawn KR20230096975A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071222P 2020-08-27 2020-08-27
US63/071,222 2020-08-27
PCT/US2021/048072 WO2022047241A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
KR20230096975A true KR20230096975A (ko) 2023-06-30

Family

ID=80353289

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010389A Withdrawn KR20230096975A (ko) 2020-08-27 2021-08-27 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법

Country Status (11)

Country Link
US (1) US20230330133A1 (https=)
EP (1) EP4203972A4 (https=)
JP (1) JP7835735B2 (https=)
KR (1) KR20230096975A (https=)
CN (1) CN116322643A (https=)
AU (1) AU2021333902A1 (https=)
BR (1) BR112023003455A2 (https=)
CA (1) CA3190563A1 (https=)
IL (1) IL300806A (https=)
MX (1) MX2023002419A (https=)
WO (1) WO2022047241A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Also Published As

Publication number Publication date
AU2021333902A1 (en) 2023-03-16
CN116322643A (zh) 2023-06-23
US20230330133A1 (en) 2023-10-19
JP7835735B2 (ja) 2026-03-25
BR112023003455A2 (pt) 2023-05-02
EP4203972A1 (en) 2023-07-05
MX2023002419A (es) 2023-07-11
IL300806A (en) 2023-04-01
CA3190563A1 (en) 2022-03-03
WO2022047241A1 (en) 2022-03-03
JP2023543133A (ja) 2023-10-13
EP4203972A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
AU2022204217B2 (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
CN108366963A (zh) 包含丹曲林的水性组合物
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
KR20230096976A (ko) 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 예방 방법
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
KR20240148426A (ko) 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료
JP2025506736A (ja) チオテパを含む安定した製剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203